08/27/2020
CLARITY ON HYDROXYCHLOROQUINE for COVID-19
HCQ (hydroxychloroquine), is FDA approved and been used to treat autoimmune disease and malaria for about 50 years. It is, currently, a controversial drug for treating Covid 19 (SARS CoV2).
FDA Approved Uses: Rheumatoid Arthritis, Lupus, Malaria
Adult Dosage per www.drugs.com:
• RA, 400-600 mg per day, 200-400 mg per day for maintenance
• Lu, 200-400 mg per day
• Ma, 800 mg initial dose, 400 mg at 6, 24, 48 hours after first dose
Side Effects: for full list, see Side Effects
Misconceptions drawn from 2005 research cast HCQ into contentious debates. Recently, some physicians and patients have reported HCQ as a cure for early CoV2 infections, while others “proved” it made infections worse, even hastening death. Both camps relied on flawed, small, incomparable cases and numbers in uncontrolled studies. However, recent research might have proved both camps to be right and wrong, within normal limitations of research and large-scale patient outcome studies.
Multiple reports indicate HCQ can be helpful and/or risky, depending on patient factors, dosage, and delivery timing. HCQ has also shown to be useless in attacking CoV2. Other researchers have reported HCQ works when used early in the disease process, and/or when combined with azithromycin (AZ), sometimes adding Zn. Different reports indicate AZ has a greater “affinity” than HCQ in preventing the virus from taking hold and replicating by directly attaching the virus’ spike protein.
Conclusion: CoV2 is a selective infector, showing certain populations are more at risk than others (African decent, all males, those with co-morbidities, blood type A). The virus attaches to the ACE2 cell site, but is often not dependent upon cell entry to initiate replication. Instead, it favors an extra cellular enzyme/protease (TMPRSS2), unphased by intra cellular HCQ. HCQ with AZ, or with AZ and Zn has been reported in recent in vitro research, and in vivo studies, to be a successful way to treat Cov2, perhaps best used early. Azithromycin studies using “quantum mechanical modeling” reported it to have a similar terminal structure to a cellular enzyme the virus uses to begin its replication process. Fooling the virus, AZ reportedly binds to the viral spike, terminating first steps for viral DNA replication. All researchers providing positive studies and pharmacological modeling rationale for treatment successes advise continued studies and research. The medical profession remains in disagreement regarding above.
Controversy
Recently, doctors from Association of American Physicians and Surgeons, claimed Covid 19 patients were successfully treated with a combination of drugs, including HCQ. They cited in vitro research from 2005 showing HCQ blocked intracellular SARS CoV1 at the ACE2 cell receptor, the same cell receptor ascribed to SARS CoV2 infections. They reported HCQ converted the infected cell from acidic, needed by SARS CoV, to slightly alkaline, and stopped viral replication. The doctors assumed it would be the same for SARS CoV2. More recent in vitro research has proven this often not to be the case.
It's the Azithromycin that is somewhat efficacious against Coronavirus-2, NOT THE hYDROXYCHLOROQUINE
Prescription drug information and news for professionals and consumers. Search our drug database for comprehensive prescription and patient information on 24,000 drugs online.
